Amedisys (AMED) Receives a Hold from Leerink Partners

Leerink Partners analyst Whit Mayo maintained a Hold rating on Amedisys (AMEDResearch Report) on March 10 and set a price target of $162.00. The company’s shares closed last Monday at $147.91, close to its 52-week low of $122.12.

According to TipRanks.com, Mayo is a 4-star analyst with an average return of 8.2% and a 56.2% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Privia Health Group, and Oak Street Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amedisys with a $185.85 average price target, implying a 25.0% upside from current levels. In a report issued on March 1, UBS also upgraded the stock to Hold with a $168.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $292.97 and a one-year low of $122.12. Currently, Amedisys has an average volume of 317.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Read More on AMED:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More